A new study led by researchers at The University of Texas MD Anderson Cancer Center shows that a specific subset of mutations in the POLE gene is strongly associated with durable responses to immunotherapy in patients with metastatic
A new study led by researchers at The University of Texas MD Anderson Cancer Center shows that a specific subset of mutations in the POLE gene is strongly associated with durable responses to immunotherapy in patients with metastatic